Loading...
•
Dec 31, 2023
Edgewise Therapeutics Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year 2023 and recent business highlights.
Key Takeaways
Edgewise Therapeutics reported fourth-quarter financial results, with R&D expenses at $27.7 million and G&A expenses at $6.2 million. The net loss for the quarter was $30.1 million, or $0.47 per share. The company's cash, cash equivalents, and marketable securities totaled approximately $318.4 million as of December 31, 2023, excluding $231.8 million in net proceeds from a January 2024 underwritten offering.
Advanced the global pivotal cohort, GRAND CANYON, of EDG-5506 in Becker muscular dystrophy (Becker).
Advanced Phase 2 LYNX trial of EDG-5506 including new cohort for boys with Duchenne muscular dystrophy (Duchenne) not currently treated with corticosteroids.
Initiating Phase 2 FOX trial in boys with Duchenne who have been previously treated with gene therapy.
Advanced Phase 1 trial of EDG-7500, a novel cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM), and other serious diseases of cardiac diastolic dysfunction.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...